总时间（秒）：13.02
问答时间（秒）：12.90

```json
[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper discusses EGFR mutations, particularly L858R, as drivers of oncogenesis and suggests that inhibiting EGFR kinase activity can reduce tumor growth.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly states EGFR mutations are drivers of cancer, linking them to disease progression and response to kinase inhibitors.",
        "next_step_or_outcome": "Proceed to Step 3"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The paper describes enzyme activity assays which evaluate the sensitivity of mutant EGFR kinase to inhibitors and helps determine the effectiveness of the inhibitors.",
        "judgment": "Yes",
        "reasoning": "Enzyme activity assays are standard in the field for evaluating the effect of mutations on protein function and drug response.  This directly models the disease mechanism as a loss of function of EGFR.",
        "next_step_or_outcome": "Proceed to Step 1a"
      },
      {
        "step_name": "Step 1a: Basic Controls and Replicates.",
        "extracted_paper_info": "The assay included EGFR kinase with the wild type L858 residue, as well as mutant EGFR kinase containing other known loss-of-function mutations, along with known gain-of-function mutations, and experiments were performed in triplicate.",
        "judgment": "Yes",
        "reasoning": "The paper specifies both positive and negative controls and details that replicates were used (in triplicate)."
      },
      {
        "step_name": "Step 1b: Statistical Analyses.",
        "extracted_paper_info": "The paper utilizes p-values and calculated OddsPath ratios to compare inhibitory effects of different compounds on L858R EGFR and wild type EGFR, showing that the L858R mutation significantly increased sensitivity.",
        "judgment": "Yes",
        "reasoning": "The paper reports p-values and OddsPath ratios to quantify the observed differences."
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_moderate"
    },
    "overall_conclusion": "The paper's description of enzyme activity assays, along with the inclusion of wild-type and other variant controls and reporting of OddsPath, supports the classification of the L858R mutation as pathogenic."
  }
]
```